Paul Jeng
Stock Analyst at Guggenheim
(4.30)
# 1,329
Out of 5,182 analysts
11
Total ratings
60%
Success rate
27.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Buy | $45 | $10.30 | +336.89% | 1 | Apr 29, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $50 → $54 | $28.19 | +91.56% | 3 | Apr 14, 2026 | |
| ADAG Adagene | Maintains: Buy | $9 → $10 | $3.82 | +161.78% | 2 | Apr 6, 2026 | |
| CNTX Context Therapeutics | Reiterates: Buy | $5 | $2.27 | +120.26% | 2 | Mar 24, 2026 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $10.79 | +76.09% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $28.16 | - | 1 | Sep 18, 2025 |
Corbus Pharmaceuticals Holdings
Apr 29, 2026
Initiates: Buy
Price Target: $45
Current: $10.30
Upside: +336.89%
IDEAYA Biosciences
Apr 14, 2026
Maintains: Buy
Price Target: $50 → $54
Current: $28.19
Upside: +91.56%
Adagene
Apr 6, 2026
Maintains: Buy
Price Target: $9 → $10
Current: $3.82
Upside: +161.78%
Context Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $5
Current: $2.27
Upside: +120.26%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $10.79
Upside: +76.09%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $28.16
Upside: -